Lupin Receives Tentative FDA Approval for Novel Apixaban Oral Suspension

Global pharmaceutical company Lupin Limited has received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. This oral liquid formulation of apixaban, the active ingredient in Eliquis®, offers an alternative administration option for adult patients requiring anticoagulation therapy, particularly those who have difficulty swallowing tablets.